Beam reports $1.2B cash post-Pfizer deal; H2 2022 IND milestones set for SCD programs

Beam Therapeutics Inc.

2021-FY EPS reported -$5.77 revenue$51,844,000

Pfizer collaboration: $300M upfront, up to $1.35B milestones for in vivo base editing programs.
Cash $1.2B including Pfizer payment; Q4 net loss $64.7M ($0.95/shr), FY net loss $370.6M ($5.77/shr).
Planned H2 2022 IND submissions: BEAM-101 (SCD Phase 1/2), BEAM-102 (SCD), BEAM-201 (T-ALL/TLL).
IND-enabling studies for BEAM-301 (liver-targeted GSDIa) in 2022; second CAR-T candidate nomination due.
R&D expenses $96.8M Q4 (up from $32.5M), G&A $17.8M Q4 (up from $8.4M) YoY.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.